Market capitalization | JPY931.07b |
Enterprise Value | JPY944.82b |
P/E (TTM) P/E ratio | 7.82 |
EV/FCF (TTM) EV/FCF | 8.06 |
EV/Sales (TTM) EV/Sales | 1.89 |
P/S ratio (TTM) P/S ratio | 1.86 |
P/B ratio (TTM) P/B ratio | 1.15 |
Dividend yield | 4.04% |
Last dividend (FY25) | JPY80.00 |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
12 Analysts have issued a Ono Pharmaceutical forecast:
12 Analysts have issued a Ono Pharmaceutical forecast:
Jun '24 |
+/-
%
|
||
Revenue | 500,332 500,332 |
9%
9%
|
|
Gross Profit | 379,127 379,127 |
9%
9%
|
|
EBITDA | 175,992 175,992 |
2%
2%
|
EBIT (Operating Income) EBIT | 158,003 158,003 |
2%
2%
|
Net Profit | 120,953 120,953 |
5%
5%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
Head office | Japan |
CEO | Gyo Sagara |
Employees | 3,853 |
Founded | 1947 |
Website | www.ono.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.